Long-term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement.
Drug survival
Golimumab
Long-term effectiveness
Psoriasis
Psoriatic arthritis
Real-life
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
22
05
2021
accepted:
28
07
2021
revised:
19
07
2021
pubmed:
20
8
2021
medline:
6
1
2022
entrez:
19
8
2021
Statut:
ppublish
Résumé
To determine the effectiveness of golimumab (GLM) in improving joint, periarticular structures and cutaneous manifestations in patients with moderate to severe psoriatic arthritis (PsA) with cutaneous psoriasis in different real-life clinical settings and 48-month drug survival. Clinical and laboratory records were collected from PsA patients treated with GLM at baseline (T0) and after 6, 12, 24, 36, and 48 months of treatment. Comparisons were performed using a paired t-test or Wilcoxon test. Drug survival rates were analyzed using Kaplan-Meier estimates. p value < 0.05 was considered statistically significant. Data from 105 patients were collected. PsO occurred in 80% of patients and enthesitis in 78%, peripheral and axial arthritis in 63.8% and 35.3%, respectively, while erosions in 36.2%. The main comorbidities were cardiovascular diseases (31.4%) and metabolic syndrome (MetS) (19%). A statistically significant improvement in articular and cutaneous psoriasis was registered at T48 of GLM-therapy in clinical (DAPSA p < 0.0001; PASI p < 0.01; BASDAI p < 0.0001) and laboratory (CRP < 0.05) indexes. Gender (p = 0.652), BMI (p = 0.655), smoking habit (p = 0.466), and line of treatment (p = 0.208) did not affect treatment efficacy nor persistence. At T48, 42% of patients discontinued GLM: the most frequent reason was an insufficient response or loss of efficacy (28.6%). A 48-month GLM high drug persistence of PsA patients was observed in real-life, in patients presenting high disease activity, elevated prevalence of comorbidities, and more than one line of treatment at baseline. Patients' characteristics as gender, smoke, BMI, different lines of treatment, and concomitant methotrexate treatment affected treatment persistence, making GLM effective and safe in moderate-severe PsA in a long-term real-life setting. Key Points • Golimumab was effective in psoriatic arthritis, including both musculoskeletal and cutaneous manifestations. • Golimumab effectiveness and drug survival were not affected by comorbidities and patient-related characteristics. • The 4-year drug survival curves confirm the efficacy and safety of golimumab in psoriatic arthritis patients in a real-life setting.
Identifiants
pubmed: 34410550
doi: 10.1007/s10067-021-05874-6
pii: 10.1007/s10067-021-05874-6
pmc: PMC8724144
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antirheumatic Agents
0
golimumab
91X1KLU43E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
75-84Informations de copyright
© 2021. The Author(s).
Références
Calabresi E, Monti S, Terenzi R, Zanframundo G, Perniola S, Carli L (2020) One year in review 2019: psoriatic arthritis. Clin Exp Rheumatol 38:1046–1055
pubmed: 33253102
Chimenti MS, Esposito M, Graceffa D, Teoli M, Peluso G, Birra D et al (2019) PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study. Ther Adv Chronic Dis 10:2040622319847056. https://doi.org/10.1177/2040622319847056
doi: 10.1177/2040622319847056
pubmed: 31205645
pmcid: 6535736
Lubrano E, Delle Sedie A, Romanelli M, Chimenti MS, Bianchi L, Piaserico S et al (2019) Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study. Clin Rheumatol. https://doi.org/10.1007/s10067-020-05482
doi: 10.1007/s10067-020-05482
pubmed: 30338414
Chimenti MS, Triggianese P, De Martino E, Conigliaro P, Fonti GL, Sunzini F et al (2019) An update on pathogenesis of psoriatic arthritis and potential therapeutic targets. Expert Rev Clin Immunol 15:823–836. https://doi.org/10.1080/1744666X.2019.1627876
doi: 10.1080/1744666X.2019.1627876
pubmed: 31177868
Chimenti MS, D’Antonio A, Conigliaro P, Ferrigno S, Vendola A, Ferraioli M, Triggianese P, Costa L, Caso F, Perricone R (2020) An update for the clinician on biologics for the treatment of psoriatic arthritis. Biologics 14:53–75. https://doi.org/10.2147/BTT.S260754
doi: 10.2147/BTT.S260754
pubmed: 32903867
pmcid: 7445514
D’Angelo S, Cantini F, Ramonda R, Cantarini L, Carletto A, Chimenti MS et al (2019) Effectiveness of adalimumab for the treatment of psoriatic arthritis: an Italian real-life retrospective study. Front Pharmacol 10:1497. https://doi.org/10.3389/fphar.2019.01497
doi: 10.3389/fphar.2019.01497
pubmed: 31920675
pmcid: 6923751
https://www.ema.europa.eu/en/medicines/human/EPAR/simponi
Kavanaugh A, McInnes IB, Mease P, Krueger GG, Gladman D, van der Heijde D, Zhou Y, Lu J, Leu JH, Goldstein N, Beutler A (2014) Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis 73:1689–1694. https://doi.org/10.1136/annrheumdis-2013-204902
doi: 10.1136/annrheumdis-2013-204902
pubmed: 24748630
Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Acosta-Felquer ML, Armstrong AW et al (2016) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68:1060–1071. https://doi.org/10.1002/art.39573
doi: 10.1002/art.39573
pubmed: 26749174
Chimenti MS, Teoli M, Saraceno R, Dattola A, Ventura A, Chiricozzi A, Chiaramonte C, Perricone R, Chimenti S (2013) Golimumab in patients affected by moderate to severe psoriatic arthritis: an open-label study in thirty-two patients previously treated with other biologics. Dermatology 227:305–310. https://doi.org/10.1159/000354263
doi: 10.1159/000354263
pubmed: 24280959
Iannone F, Favalli EG, Caporali R, D’Angelo S, Cantatore FP, Sarzi-Puttini P et al (2020) Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. Joint Bone Spine 88:105062. https://doi.org/10.1016/j.jbspin.2020.07.011
doi: 10.1016/j.jbspin.2020.07.011
pubmed: 32755721
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–73. https://doi.org/10.1002/art.21972
doi: 10.1002/art.21972
pubmed: 16871531
Gisondi P, Altomare G, Ayala F, Bardazzi F, Bianchi L, Chiricozzi A et al (2017) Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 31:774–790. https://doi.org/10.1111/jdv.14114
doi: 10.1111/jdv.14114
pubmed: 28244153
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383. https://doi.org/10.1016/0021-9681(87)90171-8
doi: 10.1016/0021-9681(87)90171-8
pubmed: 3558716
Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644
doi: 10.1161/CIRCULATIONAHA.109.192644
pubmed: 19805654
Feld J, Ye JY, Chandran V et al (2021) Axial disease in psoriatic arthritis: the presence and progression of unilateral grade 2 sacroiliitis in a psoriatic arthritis cohort. Semin Arthritis Rheum 51:464–468. https://doi.org/10.1016/j.semarthrit.2021.03.007
doi: 10.1016/j.semarthrit.2021.03.007
pubmed: 33774593
Maksymowych WP (2019) Biomarkers for diagnosis of axial spondyloarthritis, disease activity, prognosis, and prediction of response to therapy. Front Immunol 10:305. https://doi.org/10.3389/fimmu.2019.00305
doi: 10.3389/fimmu.2019.00305
pubmed: 30899255
pmcid: 6416369
Rotar Ž, Tomšič M, Praprotnik S, Rheumatologists S (2019) The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si. Clin Rheumatol 38:297–305. https://doi.org/10.1007/s10067-018-4324-7
doi: 10.1007/s10067-018-4324-7
pubmed: 30324406
Alegre-Sancho JJ, Juanola X, Rodríguez-Heredia JM, Manero J, Villa-Blanco I, Laiz A, Arteaga MJ, Cea-Calvo L, González CM (2021) Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis: a retrospective study. Medicine (Baltimore) 100:e25223. https://doi.org/10.1097/MD.0000000000025223
doi: 10.1097/MD.0000000000025223
Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DPM et al (2009) Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 11:R52
doi: 10.1186/ar2670
Jacob L, Chevalier T, Kostev K (2019) Persistence with biological drugs in patients treated in rheumatology practices in Germany. Rheumatol Int 39(3):525–531
doi: 10.1007/s00296-018-4194-y
Costa L, Perricone C, Chimenti MS, Del Puente A, Caso P, Peluso R et al (2017) Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs R D 17:509–522
doi: 10.1007/s40268-017-0215-7
Haddad A, Gazitt T, Feldhamer I et al (2021) Treatment persistence of biologics among patients with psoriatic arthritis. Arthritis Res Ther 23:44. https://doi.org/10.1186/s13075-021-02417-x
doi: 10.1186/s13075-021-02417-x
pubmed: 33514410
pmcid: 7845003
Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79:700–712. https://doi.org/10.1136/annrheumdis-2020-217159
doi: 10.1136/annrheumdis-2020-217159
pubmed: 32434812
Heiberg MS, Kaufmann C, Rødevand E, Mikkelsen K, Koldingsnes W, Mowinckel P, Kvien TK (2007) The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis 66:1038–1042. https://doi.org/10.1136/ard.2006.064808
doi: 10.1136/ard.2006.064808
pubmed: 17213251
pmcid: 1954690
Chimenti MS, Triggianese P, Conigliaro P, Tonelli M, Gigliucci G, Novelli L, Teoli M, Perricone R (2017) A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors. Clin Rheumatol 36:2253–2260. https://doi.org/10.1007/s10067-017-3769-4
doi: 10.1007/s10067-017-3769-4
pubmed: 28762060
Costa L, Caso F, Ramonda R, Del Puente A, Cantarini L, Darda MA, Caso P, Lorenzin M, Fiocco U, Punzi L, Scarpa R (2015) Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res 61:147–153. https://doi.org/10.1007/s12026-014-8595-z
doi: 10.1007/s12026-014-8595-z
pubmed: 25395342
Chimenti MS, Fonti GL, Conigliaro P, Sunzini F, Scrivo R, Navarini L et al (2020) One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Expert Opin Biol Ther 20:813–821. https://doi.org/10.1080/14712598.2020.1761957
doi: 10.1080/14712598.2020.1761957
pubmed: 32401062
Eder L, Chandran V, Gladman DD (2012) Gender-related differences in patients with psoriatic arthritis. Int J Clin Rheumatol 7:641–649
doi: 10.2217/ijr.12.63
Queiro R, Sarasqueta C, Torre JC, Tinture T, Lopez-Lagunas I (2001) Comparative analysis of psoriatic spondyloarthropathy between men and women. Rheumatol Int 21:66–68. https://doi.org/10.1007/s002960100135
doi: 10.1007/s002960100135
pubmed: 11732861
Wallenius M, Skomsvoll JF, Koldingsnes W, Rodevand E, Mikkelsen K, Kaufmann C et al (2009) Work disability and health-related quality of life in males and females with psoriatic arthritis. Ann Rheum Dis 68:685–689. https://doi.org/10.1136/ard.2008.092049
doi: 10.1136/ard.2008.092049
pubmed: 18511544
Duruöz MT, Gezer HH, Nas K, Kılıç E, Sargın B, Kasman SA et al (2021) Gender-related differences in disease activity and clinical features in patients with peripheral psoriatic arthritis: a multi-center study. Joint Bone Spine 88:105177. https://doi.org/10.1016/j.jbspin.2021.105177
doi: 10.1016/j.jbspin.2021.105177
pubmed: 33771757
Conigliaro P, Chimenti MS, Ascolani M et al (2016) Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients. Autoimmun Rev 15:184–190
doi: 10.1016/j.autrev.2015.11.002
Conigliaro P, Chimenti MS, Triggianese P et al (2021) Two years follow-up of golimumab treatment in refractory enteropathic spondyloarthritis patients with Crohn disease: a STROBE-compliant study. Medicine (Baltimore) 100:e25122. https://doi.org/10.1097/MD.0000000000025122
doi: 10.1097/MD.0000000000025122
Triggianese P, Perricone C, Conigliaro P, Chimenti MS, Perricone R, De Carolis C (2016) Peripheral blood natural killer cells and mild thyroid abnormalities in women with reproductive failure. Int J Immunopathol Pharmacol 29:65–75
doi: 10.1177/0394632015615130
Conigliaro P, D’Antonio A, Pinto S et al (2020) Autoimmune thyroid disorders and rheumatoid arthritis: a bidirectional interplay. Autoimmun Rev 19:102529. https://doi.org/10.1016/j.autrev.2020.102529
doi: 10.1016/j.autrev.2020.102529
pubmed: 32234405
Manara M, Caporali R, Favalli EG, Grosso V, Atzeni F, Sarzi Puttini P et al (2017) Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry. Clin Exp Rheumatol 35:804–809
pubmed: 28770712
Iannone F, Santo L, Anelli MG, Bucci R, Semeraro A, Quarta L et al (2017) Golimumab in real-life settings: 2 years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum 47:108–114. https://doi.org/10.1016/j.semarthrit.2017.01.008
doi: 10.1016/j.semarthrit.2017.01.008
pubmed: 28216195
Pombo-Suarez M, Sanchez-Piedra C, Garcia-Magallón B, Pérez-Gómez A, Manrique-Arija S, Martín-Doménech R et al (2021) Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry. Clin Rheumatol. https://doi.org/10.1007/s10067-021-05742-3
doi: 10.1007/s10067-021-05742-3
pubmed: 33907904